Keros Therapeutics Inc · Q1 2021 earnings

Briefing

Keros Therapeutics reported first quarter 2021 financial results.

Keros Therapeutics reported a net loss of $15.9 million in the first quarter of 2021, compared to a net loss of $11.9 million in the first quarter of 2020. The increase in net loss was primarily due to increased research and development efforts and infrastructure to support operations as a publicly traded company. Cash and cash equivalents were $255.2 million as of March 31, 2021.

• Reported a net loss of $15.9 million in the first quarter of 2021.
• Research and development expenses were $11.5 million for the first quarter of 2021.
• General and administrative expenses were $4.3 million for the first quarter of 2021.
• Cash and cash equivalents as of March 31, 2021 was $255.2 million.

Headline financials

Revenue & EPS history

Keros expects that the cash and cash equivalents it had on hand at March 31, 2021 will fund its operating expenses and capital expenditure requirements into the fourth quarter of 2023.